Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition on Standard Dose Treatment

American Journal of Cardiology

Volumn 101, Issue 4, 2008, Pages 440-445

  Angiolillo, Dominick J ^a   Costa, Marco A ^a   Shoemaker, Steven B ^a   Desai, Bhaloo ^a   Bernardo, Esther ^a   Suzuki, Yoshie ^a   Charlton, Ronald K ^b   Zenni, Martin M ^a   Guzman, Luis A ^a   Bass, Theodore A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

AGED; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 38349121677     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.09.087     Document Type: Article

References (29)

1. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., and Costa M.A. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
2. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (2005) 2430-2435
3. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55 (2006) 780-784
4. Angiolillo D.J., Bernardo E., Ramirez C., Costa M.A., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48 (2006) 298-304
5. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., Zenni M.M., Guzman L.A., Bass T.A., and Costa M.A. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
6. Angiolillo D.J., Bernardo E., Sabate M., Jimenez-Quevedo P., Costa M.A., Palazuelos J., Hernandez R., Moreno R., Escaned J., Alfonso F., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 (2007) 1541-1547
7. Geisler T., Anders N., Paterok M., Langer H., Stellos K., Lindemann S., Herdeg C., May A.E., and Gawaz M. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 30 (2007) 372-374
8. Urban P., Gershlick A.H., Guagliumi G., Guyon P., Lotan C., Schofer J., Seth A., Sousa J.E., Wijns W., Berge C., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113 (2006) 1434-1441
9. Kuchulakanti P.K., Chu W.W., Torguson R., Ohlmann P., Rha S.W., Clavijo L.C., Kim S.W., Bui A., Gevorkian N., Xue Z., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
10. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
11. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Juni P., Sianos G., Hellige G., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
12. von Beckerath N., Pogatsa-Murray G., Wieczorek A., Sibbing D., Schomig A., and Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 95 (2006) 910-911
13. von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., and Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112 (2005) 2946-2950
14. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Banuelos C., Hernandez-Antolin R., Escaned J., Moreno R., Alfonso F., and Macaya C. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25 (2004) 1903-1910
15. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., Moschi G., Gori A.M., Abbate R., and Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
16. Montalescot G., Sideris G., Meuleman C., Bal-dit-Sollier C., Lellouche N., Steg P.G., Slama M., Milleron O., Collet J.P., Henry P., et al. A randomized comparison of high clopidogrel loading-doses in patients with non-ST-elevation acute coronary syndromes: the ALBION trial. J Am Coll Cardiol 48 (2006) 931-938
17. Cuisset T., Frere C., Quilici J., Morange P.E., Nait-Saidi L., Carvajal J., Lehmann A., Lambert M., Bonnet J.L., and Alessi M.C. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
18. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) study. Circulation 111 (2005) 2099-2106
19. Lotrionte M., Biondi-Zoccai G.L., Agostoni P., Abbate A., Angiolillo D.J., Valgimigli M., Moretti C., Meliga E., Cuisset T., Montalescot G., et al. Metaanalysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 100 (2007) 1199-1206
20. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Cavallari U., Trabetti E., Sabate M., Hernandez R., Moreno R., Escaned J., et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26 (2006) 1895-1900
21. Angiolillo D.J., Fernández-Ortiz A., Bernardo E., Ramirez C., Cavallari U., Trabetti E., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol 96 (2005) 1095-1099
22. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 97 (2006) 38-43
23. Kastrati A., von Beckerath N., Joost A., Pogatsa-Murray G., Gorchakova O., and Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110 (2004) 1916-1919
24. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., Morrison D.A., O'Neill W.W., Schaff H.V., Whitlow P.L., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) e1-e121
25. von Beckerath N., Kastrati A., Wieczorek A., Pogatsa-Murray G., Sibbing D., Graf I., and Schomig A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28 (2007) 1814-1819
26. Angiolillo D.J., and Alfonso F. Clopidogrel-statin interaction: myth or reality?. J Am Coll Cardiol 50 (2007) 296-298
27. Alfonso F., and Angiolillo D.J. Platelet function assessment to predict outcomes after coronary interventions: hype or hope?. J Am Coll Cardiol 48 (2006) 1751-1754
28. Angiolillo D.J., and Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost 98 (2007) 707-709
29. Angiolillo DJ. ADP receptor antagonism: what's in the pipeline? Am J Cardiovasc Drugs. In press.